SeraCare Life Sciences acquired the Teragenix T-20 Drug Resistance Panel (HIVDRP-002a) in 2008. This is a panel of naturally occurring plasma specimens from HIV infected individuals demonstrating multiple reverse transcriptase and protease associated mutations. Package of 10 members, reactive for HIV RNA. 1 vial per member.
For Research Use Only. Not for use in diagnostic procedures.